<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Foster, R.S.</title>
    <link>http://repub.eur.nl/res/aut/13880/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Predicting Retroperitoneal Histology in Postchemotherapy Testicular Germ Cell Cancer: A Model Update and Multicentre Validation with More Than 1000 Patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/10708/</link>
      <pubDate>2006-07-14T00:00:00Z</pubDate>
      <description>Objectives: Surgical resection of postchemotherapy retroperitoneal lymph nodes is often
performed in patients with advanced nonseminomatous testicular germ cell cancer. We
previously developed a model to predict the probability that the lymph nodes contain only
necrotic or fibrotic (benign) tissue versus mature teratoma and viable cancer (tumour) to
identify patients who actually need resection. The present study used an updated model
with new patient data and studied the validity of the updated model across various settings.
Methods: We combined data of 544 patients from the original model with data of 550 new
patients and performed a new logistic regression analysis, which included the same six
predictors: histology of the primary tumour, prechemotherapy serum levels of a-fetoprotein,
human chorionic gonadotropin, lactate dehydrogenase, residual mass size measured
on computed tomography, and change in mass size. The validity of the updated model was
studied in individual centres. Calibration of the predicted probabilities was assessed
graphically and with the Hosmer-Lemeshow test. Discrimination was studied with the
concordance (c)-statistic.
Results: The updated model had slightly different, although more precise, regression
coefficients. Statistically nonsignificant Hosmer-Lemeshow tests confirmed good calibration
in most centres. The c-statistic for all centres except one exceeded 0.80. The updated
model was valid over the complete range of predicted probabilities across a broad spectrum
of centres.
Conclusions: This finding gives confidence in the applicability of the model to select patients
for resection, particularly patients with small residual masses and low predicted probabilities
of benign tissue (i.e., substantial predicted risks of residual tumour).</description>
    </item>
  </channel>
</rss>